hrp0092p1-364 | GH and IGFs (2) | ESPE2019

GH Values in Serum and Blood Spots on Filter Paper Samples in Neonates Until 30 Days of Life by Electrochemiluminescence (ECLIA).

Miras Mirta , Silvano Liliana , Campi Veronica , Ochetti Mariana , Sobrero Gabriela , Castro Laura , Martin Silvia , Testa Graciela , Franchioni Liliana

Growth Hormone deficiency (GHD) in newborn is an infrequent condition, which can cause threat to life due mainly to hypoglycemia that begins in the first week of life. A GH basal level (whether random or associated with spontaneous hypoglycemia) that distinguishes infants with GHD from those with GH sufficiency in the neonatal period is not conclusive. Few data have been reported about the GH measurements in serum and dried blood spots on filter paper samples in healthy neonat...

hrp0092p2-167 | GH and IGFs | ESPE2019

Adherence and Long-Term Outcomes of Therapy in Pediatric Subjects in Argentina using Easypod™ Electromechanical Device for Growth Hormone Treatment: The Phase IV Multicentre Easypod™ Connect Observational Study (ECOS)

Chareca Cinthia D , Belgorosky Alicia , Chiarpenello Javier , Colombi Lia , Pasqualini Titania , Von Schulz Hausmann Cristian , Assefi Aria , miras mirta

The Easypod™ Connect Observational Study (ECOS) assessed real-time adherence in patients from 24 countries who were receiving recombinant human growth hormone (r-hGH; Saizen®) via easypod™, which is an electronic injection device. Overall, ECOS showed mean adherence was maintained at ~80% for up to 3 years. Here, we assess the adherence to r-hGH administered via easypod™ in the Argentinian cohort of patients from ECOS (NCT01582334).<p class="ab...

hrp0086p1-p896 | Thyroid P1 | ESPE2016

Iodide Transport Defect: Identification of a Novel Mutation in the Carboxy-terminus of the Sodium/iodide Symporter in a Pediatric Patient with Congenital Hypothyroidism

Nicola Juan Pablo , Martin Mariano , Signorino Malvina , Testa Graciela , Sobrero Gabriela , Munoz Liliana , Masini-Repiso Ana Maria , Miras Mirta

Iodide (I−) transport defect (ITD) is an autosomal recessive disorder caused by the inability of the thyroid follicular cell to actively accumulate iodide. Active I− accumulation is mediated by the Na+/I− symporter (NIS), an integral plasma membrane glycoprotein located on the basolateral surface of thyrocytes. The diagnostic criteria for ITD include a variable degree of hypothyroidism and goiter, low to absent thyr...

hrp0082p2-d1-459 | Growth | ESPE2014

Comparison Between GH assay: serum GH Cut-off Levels by ECLIA Performed in Pharmacological Estimulation Tests in Children With Short Stature

Aguirre Cecilia , Sobrero Gabriela , Schvab Giselle , Silvano Liliana , Alvarez Julia , Ochetti Mariana , Lescurat Maria , Paez Alejandra , Munoz Liliana , Martin Silvia , Miras Mirta

Background: The diagnosis of GH deficiency in children is based on clinical, auxological, radiographic and biochemical criteria which include response to Pharmacological Estimulation Tests (PhT). It is well known that GH concentrations vary according to the assay method used. Currently in our population, the proposed cut-off value of serum GH PhT is 4.7 ng/ml measured by ICMA using the IRP 98/574.Objective and hypotheses: The aims of this study were to d...

hrp0095p1-360 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Somatostin analogs in a 15 year old boy with gigantism

Hernandez Claudia , Rodriguez Saa Magdalena , Fernandez Ivana , Figurelli Silvina , Daly Adrian , Guitelman Mirta

Introduction: Pituitary gigantism is caused by a somatotroph pituitary tumor that occurs before epiphyseal closure and is associated with increased morbidity due to the systemic effects of chronic hormonal excess. It is an extremely rare disease, with an estimated incidence of 8 per million person-years. Therapeutic modalities for pituitary gigantism are the same as those for acromegaly and include surgery, medication and radiation. Medical treatment plays an ...

hrp0092p2-228 | Pituitary, Neuroendocrinology and Puberty | ESPE2019

Near Adult Height According to Genetic Target and Absence Of Craniofacial Bone Fibrous Dysplasia in a Girl With Mc Cune Albright Syndrome and Growth Hormone Excess: 12.6 Years Follow-up

Fernández Mentaberry Verónica , Riu Carmen , Oneto Adriana , Stivel Mirta

Background: Mc Cune Albright (MAS), is a rare genetic disease clinically defined by bone fibrous dysplasia (BFD), café au lait skin spots and at least one hyperfunction endocrinopathy. Growth Hormone (GH) excess has been described in 20% of patients usually accompanied by hyperprolactinemia (80%). As reported in literature GH hypersecretion is allways associated with craniofacial BFD, macrocephaly and is also accompanied by higher risk of systemic...

hrp0094p2-365 | Pituitary, neuroendocrinology and puberty | ESPE2021

Gonadotropin Flare with Different Depot GnRH Agonists: Comparative Analysis.

Freire Analia , Arcari Andrea , Gabriela Ballerini Maria , Ignacio Bergada , Gabriela Ropelato Maria , Gryngarten Mirta ,

Central precocious puberty (CPP) is effectively treated by inhibition of GnRH signaling through GnRH receptor desensitization with depot GnRH agonists (dGnRHa), but the first injection is associated with a surge in LH and FSH (flare) that proportionally increases estradiol levels. When estradiol levels drop, usually within a fortnight, vaginal bleeding may be seen in a small number of girls. Although dGnRHa that use higher, longer-acting doses are increasingly being used in gi...

hrp0097p1-159 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Long-Term Effect of Gonadotropin-Releasing Hormone Analogue Therapy on Adult Height in Girls with Central Precocious Puberty Diagnosed before 4 Years of Age

Freire Analía , Gryngarten Mirta , Gabriela Ballerini María , Vieites Ana , Gabriela Ropelato María , Arcari Andrea

Background: Central precocious puberty (CPP) is uncommon before the age of 4 and treatment with GnRH analogues have shown unequivocal benefits. CPP during or near mini puberty entails differential clinical and biochemical features in the diagnosis and leads to longer treatment and follow-up. There are very limited studies with long-term outcomes about CPP girls exclusively < 4 years of age regarding growth, menarche, and adult height after GnRHa withdrawal....

hrp0089p2-p355 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology P2 | ESPE2018

Adiponectin as a Marker of Peripheral Insulin Resistance in Adolescents with Polycystic Ovarian Syndrome (PCOS) and as a Tool to Suspect Insulin Receptor Defects

Freire Analia , Gryngarten Mirta , Ballerini Maria Gabriela , Arcari Andrea , Bengolea Sonia Viviana , Scaglia Paula , Bergada Ignacio , Ropelato Maria Gabriela

Background: Decreased serum adiponectin levels are associated with obesity and peripheral insulin resistance (IR). PCOS is characterized by hyperandrogenism and chronic anovulation and frequently is associated to IR. Some defects of Insulin Receptor have been proposed as mechanisms to explain ovarian hyperandrogenism in PCOS.Objectives: To explore adiponectin levels in adolescents with PCOS and to evaluate if adiponectin would identify potential patients...

hrp0086p2-p774 | Pituitary and Neuroendocrinology P2 | ESPE2016

Insulin Sensitivity in Girls with Central Precocious Puberty at Diagnosis and at 6 Months of GnRH Analogue Treatment

Arcari Andrea , Freire Analia , Escobar Maria Eugenia , Ballerini Maria Gabriela , Ropelato Maria Gabriela , Bergada Ignacio , Gryngarten Mirta

Background: Puberty is associated with a physiological decline in insulin sensitivity. Overweight and obesity are common among girls with Central Precocious Puberty (CPP). CPP and early menarche have been considered as risk factors for obesity and cardiovascular diseases during adulthood. Besides, concern has been raised by the potential impact of GnRH analogues (GnRH-a) treatment on body weight and metabolic profile.Objective and hypotheses: To evaluate...